Entrada Therapeutics
TRDA
TRDA
38 hedge funds and large institutions have $302M invested in Entrada Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 17 closing their positions.
Holders
38
Holders Change
-10
Holders Change %
-20.83%
% of All Funds
0.64%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
8
Increased
5
Reduced
15
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Vanguard Group
Malvern,
Pennsylvania
|
$9.29M |
| 2 |
CA
2
CHI Advisors
New York
|
$1.99M |
| 3 |
BBA
3
Baker Bros. Advisors
New York
|
$59.3M |
| 4 |
LCM
4
Laurion Capital Management
New York
|
$1.57M |
| 5 |
5
Millennium Management
New York
|
$932K |
Top Sellers
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| – | – | -848 | Closed |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| – | – | -708 | Closed |
|
53
Nisa Investment Advisors
St. Louis,
Missouri
| – | – | -700 | Closed |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | – | -646 | Closed |
|
|
CFGS
55
Concourse Financial Group Securities
Birmingham,
Alabama
| – | – | – | – |
|
|
CS
56
Credit Suisse
Zurich,
Switzerland
| $0 | 6 | +6 | New |
|